Results 131 to 140 of about 13,301,732 (374)

Discovery of an Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B

International Journal of Molecular Sciences, 2019
Hemophilia B is a severe blood clotting disorder caused by the deficiency of factor IX (FIX). FIX is not bioavailable when given orally due to poor stability and permeability in the gastrointestinal tract.
Chen Xie, Zhijun Wang, Yang Su, Jeffrey R. Wang, W. Shen   +4 more
semanticscholar   +1 more source

Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study [PDF]

, 2019
Introduction: Ultrasound (US) assessment of joints is an evolving point of care tool for the detection of early joint arthropathy (Napolitano M, Kessler CM. Hemophilia A and B.
Di Minno, Giovanni, Di Minno, Matteo Nicola Dario, Mancuso, Salvatrice, Mansueto, Maria Francesca, Mauro, Giulia Letizia, Napolitano, Mariasanta, Raso, Simona, Scaturro, Dalila, Siragusa, Sergio   +8 more
core   +1 more source

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management of VWD all utilised GRADE methodology.
Mark W. Skinner, Manuela Albisetti, Jesús Ardila, Jan Astermark, Jan Blatny, Manuel Carcao, Pratima Chowdary, Nathan T. Connell, Miguel Crato, Yesim Dargaud, Roseline d'Oiron, Amy L. Dunn, Miguel A. Escobar, Carmen Escuriola‐Ettingshausen, Emna Gouider, Annie Harroche, Cedric Hermans, Victor Jimenez‐Yuste, Radoslaw Kaczmarek, Gili Kenet, Liane Khoo, Robert Klamroth, Florian Langer, David Lillicrap, Johnny Mahlangu, Christoph Male, Tadashi Matsushita, Sandrine Meunier, Wolfgang Miesbach, Beatrice Nolan, Johannes Oldenburg, Brian O'Mahony, Margareth Ozelo, Glenn F. Pierce, Gloria Ramos, Michael Recht, Olivia Romero‐Lux, Dawn Rotellini, Rita C. Santoro, Tammuella C. Singleton, Alok Srivastava, Sophie Susen, Kate Talks, Huyen Tran, Leonard A. Valentino, Jerzy Windyga, Renchi Yang, Maria Elisa Mancuso, also on behalf of AICE, AHAD‐AP, AHCDC, ATHN, CLAHT, EHC, French CRH & MHEMO, HTCCNC, NBDF, PEDNET, UKHCDO, WFH   +59 more
wiley   +1 more source

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy

Molecular Therapy: Methods & Clinical Development, 2019
Hemophilia A (HA) and hemophilia B (HB) are X-linked bleeding disorders due to inheritable deficiencies in either coagulation factor VIII (FVIII) or factor IX (FIX), respectively.
Benjamin J. Samelson-Jones, Valder R. Arruda   +1 more
doaj  

Emergencies in Hemophiliacs

Journal of Education and Teaching in Emergency Medicine, 2016
Audience: This modified team-based learning (mTBL) session is appropriate for medical students or emergency medicine residents. Introduction: Hemophilia is an x-linked recessive disorder leading to a decrease in functional clotting factors; there ...
Alisa Wray
doaj   +1 more source

Optimal evaluations for the Sándor-Yang mean by power mean [PDF]

arXiv, 2015
In this paper, we prove that the double inequality $M_{p}(a,b)0$ with $a\neq b$ if and only if $p\leq 4\log 2/(4+2\log 2-\pi)=1.2351\cdots$ and $q\geq 4/3$, where $% M_{r}(a,b)=[(a^{r}+b^{r})/2]^{1/r}$ $(r\neq 0)$ and $M_{0}(a,b)=\sqrt{ab}$ is the $r$th power mean, $B(a,b)=Q(a,b)e^{A(a,b)/T(a,b)-1}$ is the S\'{a}%
arxiv  

Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update

Haemophilia, Volume 31, Issue 2, Page 247-262, March 2025.
ABSTRACT Background Von Willebrand disease (VWD) is an inherited bleeding disorder caused by deficient or dysfunctional von Willebrand factor (VWF). VWF replacement therapy is indicated in VWD management. Methods This systematic review was conducted to evaluate all available evidence of the efficacy, safety, dosing and consumption of pasteurized plasma‐
Carmen Escuriola Ettingshausen, Riitta Lassila, Gines Escolar, Christoph Male, Kathrin Schirner, Lisa Heyder, Erik Berntorp   +6 more
wiley   +1 more source

Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study

Patient Related Outcome Measures, 2019
Tyler W Buckner,1 Robert Sidonio Jr,2 Michelle Witkop,3 Christine Guelcher,4 Susan Cutter,5 Neeraj N Iyer,6 David L Cooper6 1Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Aurora, CO, USA; 2Department of Pediatrics, Aflac ...
Buckner TW, Sidonio Jr R, Witkop M, Guelcher C, Cutter S, Iyer NN, Cooper DL   +6 more
doaj  

Natural Cohen-Macaulayfication of simplicial affine semigroup rings [PDF]

arXiv, 2010
Let $K$ be a field, $B$ a simplicial affine semigroup, and $C(B)$ the corresponding cone. We will present a decomposition of $K[B]$ into a direct sum of certain monomial ideals, which generalizes a construction by Hoa and St\"uckrad. We will use this decomposition to construct a semigroup $\tilde B$ with $B \subseteq \tilde B \subseteq C(B)$ such that $
arxiv  

A Comparison between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Congenital Factor VII Deficiency [PDF]

, 2015
In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 1/4g/kg, intravenously per week for 4 weeks, in a randomized fashion. The
Abolghasemi, H., Ahmadinejad, M., Baghaeipour, M.R., Dehdezi, B.K., Eshghi, P., Faranoush, M., Fayazfar, R., Heshmat, R., Hoorfar, H., Kamyar, K., Karimi, M., Khoeiny, B., Managhchi, M., Mehrvar, A., Mirbehbahani, N.B., Naderi, M., Toogeh, G.   +16 more
core